Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicities
研究概览
简要总结
Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH.
Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH.
We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
详细描述
An open-label, safety, tolerability, and dose-finding study using the continuous reassessment method.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •The diagnosis of ICH is confirmed by brain CT scan.
- •The first dose of the study drug can be administered within 18 hours of ICH symptom onset.
- •Signed and dated informed consent is obtained
- •Stable clinical and neurological status. Patients whose clinical or neurological status significantly deteriorates compared to presentation prior to administration of the study drug will be excluded.
排除标准
- •Previous chelation therapy or known hypersensitivity to DFO products
- •Abnormal renal function (serum creatinine > 2 mg/dl)
- •Known severe iron deficiency anemia
- •Planned surgical evacuation of ICH prior to administration of the study drug
- •Patients with suspected secondary ICH related to tumour, coagulopathy, ruptured aneurysm or arteriovenous malformation, or venous sinus thrombosis
- •Evidence of significant shift of midline brain structure (> 10 mm) or herniation on imaging studies.
- •Deep coma (Glasgow Coma Score (GCS) = 3-5) upon presentation
- •Taking iron supplements or prochlorperazine
- •Patients with heart failure taking > 500 mg of vitamin C daily
- •Known hearing impairment
- •Systolic blood pressure < 100 mmHg or diastolic blood pressure < 60 mmHg, confirmed by 3 consecutive readings
- •Significant chronic respiratory insufficiency
- •Known pregnancy (or positive pregnancy test), or breast-feeding
- •Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, incompliance, or any other cause.
- •Any condition which, in the judgement of the investigator, might increase the risk to the patient
- •Life expectancy of less than 90 days due to co-morbid conditions
- •Concurrent participation in another research protocol for investigation of another experimental therapy
- •Pre-existing Do Not Resuscitate (DNR) order, or indication that a new DNR order will be implemented within the first 48 hours of hospitalization. -
研究组 & 干预措施
1
All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.
干预措施: Deferoxamine Mesylate (Drug)
结局指标
主要结局
Dose-limiting toxicities
时间窗: First 7 days of hospitalization or diacharge, whichever occurs earlier
次要结局
未报告次要终点
研究者
Magdy Selim
Professor of Neurology
Beth Israel Deaconess Medical Center